Whanin Pharmaceutical said that it would exclusively market Cariprazine, a schizophrenia treatment developed by Gedeon Richter, in Korea.
Under the accord, the company will commercialize, distribute, sell, conduct local clinical trials and apply for item license for Cariprazine, while its Hungarian partner will supply the drug.
Cariprazine is a once-a-day oral administration for schizophrenia that was approved and marketed in the United States and 15 European countries.
In the U.S., Allergan markets the drug for the treatment of adult type 1 bipolar disorder and schizophrenia. In Europe, Gedeon Richter and Recordati sell the medicine for the treatment of adult schizophrenia.
“We look forward to building partnerships with Gedeon Richter to strengthen our influence in our major business area of neuropsychiatric treatment,” Whanin CEO Lee Won-bum said. “We are pleased to offer Cariprazine as a new treatment option for Korean patients and medical professionals.”
Gedeon Richter CEO Gábor Orbán also said, “South Korea will play a key role in the growth of Cariprazine as a global new drug.”
The company believes that Whanin, which has strong market leadership and sales in the field of the central nervous system, is the best partner for Cariprazine in the Korean market, Orbán added.
<© Korea Biomedical Review, All rights reserved.>